90 related articles for article (PubMed ID: 23235972)
41. [A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
Gan To Kagaku Ryoho; 2006 Jun; 33(6):841-4. PubMed ID: 16770110
[TBL] [Abstract][Full Text] [Related]
42. Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Birtle AJ; Newby JC; Harland SJ
Br J Cancer; 2004 Oct; 91(8):1472-6. PubMed ID: 15381936
[TBL] [Abstract][Full Text] [Related]
43. Challenges and recommendations for early identification of metastatic disease in prostate cancer.
Crawford ED; Stone NN; Yu EY; Koo PJ; Freedland SJ; Slovin SF; Gomella LG; Berger ER; Keane TE; Sieber P; Shore ND; Petrylak DP;
Urology; 2014 Mar; 83(3):664-9. PubMed ID: 24411213
[TBL] [Abstract][Full Text] [Related]
44. Reversal of docetaxel resistance with bevacizumab and thalidomide.
Ning YM; Figg WD; Dahut WL
Clin Genitourin Cancer; 2009 Aug; 7(2):E37-8. PubMed ID: 19692321
[TBL] [Abstract][Full Text] [Related]
45. [Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Kusukawa N; Ishida H; Tanase K; Ito H; Aoki Y; Ooyama N; Akino H; Yokoyama O
Hinyokika Kiyo; 2013 May; 59(5):301-4. PubMed ID: 23719139
[TBL] [Abstract][Full Text] [Related]
46. [Chemotherapy of hormone-resistent cancer of the prostate].
Matveev BP; Bukharkin BV; Kalinin SA
Urologiia; 2005; (4):20-3. PubMed ID: 16158740
[TBL] [Abstract][Full Text] [Related]
47. Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
George DJ
Clin Adv Hematol Oncol; 2019 Jul; 17(7):382-385. PubMed ID: 31449503
[No Abstract] [Full Text] [Related]
48. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.
Myers C; Cooper M; Stein C; LaRocca R; Walther MM; Weiss G; Choyke P; Dawson N; Steinberg S; Uhrich MM
J Clin Oncol; 1992 Jun; 10(6):881-9. PubMed ID: 1375283
[TBL] [Abstract][Full Text] [Related]
49. Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?
Nabhan C
J Clin Oncol; 2008 May; 26(14):2413-4; author reply 2414-5. PubMed ID: 18467737
[No Abstract] [Full Text] [Related]
50. Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
Al-Chalabi T; Figg WD
Cancer Biol Ther; 2007 Mar; 6(3):318-9. PubMed ID: 17471018
[No Abstract] [Full Text] [Related]
51. Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument against.
Jewett MA; Khakpour G; Moore MJ
Eur Urol; 1996; 29 Suppl 2():45-8. PubMed ID: 8717463
[TBL] [Abstract][Full Text] [Related]
52. [Comment to P. J. Olbert et al., page 164].
Heidenreich A
Aktuelle Urol; 2009 May; 40(3):169-70. PubMed ID: 19479669
[No Abstract] [Full Text] [Related]
53. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.
Rosenbaum E; Carducci MA
Expert Opin Pharmacother; 2003 Jun; 4(6):875-87. PubMed ID: 12783585
[TBL] [Abstract][Full Text] [Related]
54. Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Bracarda S
Eur Urol; 2007 Dec; 52(6):1698-9. PubMed ID: 17306444
[No Abstract] [Full Text] [Related]
55. Metastatic prostate cancer.
Mehdi I
J Pak Med Assoc; 2002 Feb; 52(2):52-3. PubMed ID: 12073708
[No Abstract] [Full Text] [Related]
56. Research in drug development for advanced prostate cancer.
Eisenberger M
Clin Adv Hematol Oncol; 2018 Jan; 16(1):42-44. PubMed ID: 29741504
[No Abstract] [Full Text] [Related]
57. Prostate cancer: thalidomide for prostate cancer: is there progress?
Efstathiou E; Logothetis CJ
Nat Rev Urol; 2009 May; 6(5):248-50. PubMed ID: 19424170
[TBL] [Abstract][Full Text] [Related]
58. Weekly low-dose adriamycin in hormone-resistant metastatic cancer of the prostate.
Fosså SD; Urnes T; Kaalhus O
Scand J Urol Nephrol; 1987; 21(1):13-6. PubMed ID: 2438753
[TBL] [Abstract][Full Text] [Related]
59. Computational modelling of resistance and associated treatment response heterogeneity in metastatic cancers.
Turk M; Simončič U; Roth A; Valentinuzzi D; Jeraj R
Phys Med Biol; 2019 May; 64(11):115001. PubMed ID: 30790781
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate.
Berry WR; Laszlo J; Cox E; Walker A; Paulson D
Cancer; 1979 Aug; 44(2):763-75. PubMed ID: 476583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
